TBFA

TBFA
Product Description

High purity target compounds in solid phase (amorphous/crystalline form) rather than oil phase.

Detailed technologies: 1) High-purity synthesis technology 
2) Separation and purification technology            
3) Crystallization technology

Read more Show less

MFC Co.,Ltd.

  • KR
  • 2022
    On CPHI since
  • 3
    Certificates
  • 50 - 99
    Employees
Company types
CMO/CDMO
Generics/Biosimilars Manufacturer
Manufacturer/Innovator
Primary activities
API Producer
Generic APIs producer
View company profile
Categories
more categories Show less
Specifications
  • CAS Registry Number
    124752-23-4
  • Details

    In-House

  • Selling Points
    Price; Prompt Delivery; Quality Service
  • Supplied from
    Korea, Republic Of
  • Measured In
    kilogram
More specifications Fewer specifications
Sales Markets
Show more Show less

MFC Co.,Ltd.

  • KR
  • 2022
    On CPHI since
  • 3
    Certificates
  • 50 - 99
    Employees
Company types
CMO/CDMO
Generics/Biosimilars Manufacturer
Manufacturer/Innovator
Primary activities
API Producer
Generic APIs producer
View company profile

More Products from MFC Co.,Ltd. (1)

  • Synthesis of APIs

    Product Synthesis of APIs

    APIs:  Pitavastatin Calcium Hydrate, Rosuvastatin Calcium, Donepezil, Clopidogrel Bisulfate, Sarpogrelate Hydrochloride, Erdosteine, Pelubiprofen, (S)-Amlodipine Besylate 2.5 Hydrate, (S)-Pantoprazole Sodium Trihydrate

    Intermediates of Statins:
    MRV-1, ...

MFC Co.,Ltd. resources (1)

  • MFC Co.,Ltd

    Video MFC Co.,Ltd

    MFC Co., Ltd., established in 2008, is a manufacturer specializing in APIs and key intermediates, which GMP certified from KMFDS. MFC is continuously developing under quality management through thorough quality control and quality assurance system, and technology management that put best efforts in continuous process improvement and new technology development. MFC's direction and aim are the development of new excellent new APIs and intermediates, CMO/CDMO business in accordance with customer requirements, and Incrementally Modified Drugs (IMD) & New Chemical Entity (NCE) using specialized technologies to go forward as a global pharmaceutical company.
    2024-09-23